# A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

> **NCT05885412** · PHASE1 · RECRUITING · sponsor: **Rocket Pharmaceuticals Inc.** · enrollment: 9 (estimated)

## Conditions studied

- PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

## Interventions

- **GENETIC:** RP-A601

## Key facts

- **NCT ID:** NCT05885412
- **Lead sponsor:** Rocket Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-29
- **Primary completion:** 2028-09
- **Final completion:** 2029-09
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885412, "A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05885412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*